Retatrutide 10mg
Original price was: $130.00.$120.00Current price is: $120.00.
- Description
- SIDE EFFECTS
- DOSAGES
Description
Retatrutide 10mg
Retatrutide is a groundbreaking first-in-class triple agonist that targets glucagon receptors, gastric inhibitory polypeptide (GIP), and glucagon-like peptide-1 (GLP-1) receptors simultaneously. This innovative peptide works through a synergistic interaction among these receptors, resulting in increased insulin secretion, improved glucose homeostasis, refined appetite modulation, and enhanced energy expenditure.
Currently in Phase III development for obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease, retatrutide has demonstrated remarkable efficacy in clinical trials. Phase II trials showed significant weight reduction, with average losses of 17.5% and 24.4% at 24 and 48 weeks respectively. In a recent Phase III trial for type 2 diabetes, retatrutide achieved up to 2% A1C improvement and nearly 17% weight loss in 40 weeks of treatment.
The peptide has also shown potential cardiovascular benefits by improving key risk factors including non-HDL cholesterol, triglycerides, and systolic blood pressure. The most common adverse events reported are consistent with other incretin-based therapies, including nausea and diarrhea, particularly at higher doses. With seven additional Phase III trials expected to complete in 2026, retatrutide represents a promising advancement in the treatment of metabolic disorders.
Gastrointestinal symptoms are the most common side effects of retatrutide, including nausea (up to 60% at 12 mg), diarrhea (15–33%), vomiting (21–26%), and constipation (11–16%). These effects are dose-dependent and typically peak during dose escalation (weeks 6–8) before subsiding as the body adjusts.
Other notable side effects include dysesthesia (tingling or altered skin sensation, affecting 20.9% at 12 mg), a mild increase in heart rate (5–10 bpm), decreased appetite, and injection site reactions. Serious adverse events occur at rates comparable to placebo (4%), and most participants tolerate the medication well despite initial GI distress
Retatrutide is an investigational triple-hormone-receptor agonist currently in Phase 2 clinical trials for obesity treatment and is not yet FDA-approved for general clinical use. In clinical trials, the medication was administered via subcutaneous weekly injections with a standard titration schedule starting at 2 mg or 4 mg for the first four weeks, then escalating every four weeks to target doses of 4 mg, 8 mg, or 12 mg.
Clinical Trial Dosing and Efficacy
Standard Protocol: Most participants started at 2 mg weekly (some at 4 mg) and increased to 4 mg at week 4, 8 mg at week 8, and up to 12 mg at weeks 12–16, depending on tolerability.
Gender Differences: Trial data indicates that women often achieve superior weight loss outcomes compared to men across all dose groups, with some sources suggesting fit women may require lower maintenance doses (e.g., ~1–2 mg) than fit men (~2 mg) for metabolic optimization, though clinical targets often aim higher.
Maximum Efficacy: The 12 mg weekly dose produced the most significant results in trials, with female participants achieving an average weight loss of 25.3% and male participants 22.8% of body weight over 48 weeks.
Unofficial/Community Dosing Charts Non-clinical sources and peptide vendors often propose specific weekly titration charts that differ from the NEJM Phase 2 trial protocols:
Men: Often suggested to start at 2.5 mg and escalate to 15 mg over 12 weeks (e.g., 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg).
Women: Often suggested to start at 2 mg and escalate to 12.5 mg over 12 weeks (e.g., 2 mg → 3.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg), with some recommendations to stop at 8 mg if appetite is controlled due to higher sensitivity.
Important Safety Note: Because retatrutide is not yet approved, there are no standardized dosing guidelines for clinical practice. Dosing in trials was adjusted every 4 weeks based on side effects, primarily gastrointestinal issues like nausea. Consult a healthcare professional for personalized medical advice once regulatory approval is granted.
